investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 CAMBRIDGE, Mass. , & PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 9, 2019-- bluebird bio, Inc.Read more
More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a β 0 / β 0 genotype Ninety percent of evaluable patients who do not have a β 0 / β 0Read more
99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment Group C patients at six months post-treatmentRead more